Results 101 to 110 of about 25,658,089 (295)
Topoisomerase I inhibitors are a new class of anticancer agents with a mechanism of action aimed at interrupting DNA replication in cancer cells, the result of which is cell death. Most if not all Topoisomerase I inhibitors are derivatives of the plant extract camptothecin.
, Ewesuedo, , Ratain
openaire +1 more source
Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry
Objective Cancer represents a major cause of death in systemic sclerosis (SSc). Established risk factors are limited to specific subsets, particularly early diffuse anti‐RNA polymerase III (POLR3)–positive disease, needing further exploration. Methods We performed a nested case‐control study within the European Scleroderma Trials and Research group ...
Antonio Tonutti +52 more
wiley +1 more source
New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads. [PDF]
Pommier Y, Thomas A.
europepmc +1 more source
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis +5 more
wiley +1 more source
Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors. [PDF]
Madkour MM +3 more
europepmc +1 more source
. Aims Traditional pharmacovigilance detects single drug–event associations but cannot readily characterize multi‐system adverse‐event patterns such as fluoroquinolone‐associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar.
Niaz Chalabianloo +3 more
wiley +1 more source
Background: Isoindolo[2,1-alpha] quinoxalines constitute an important class of compounds which demonstrated potent antiproliferative activity against different human tumor cell lines and topoisomerase I inhibitors.
CASCIOFERRO, Stella Maria +15 more
core +1 more source
Harnessing the light‑switch properties of Ru‑PDC3, we demonstrate that it binds to G‑quadruplex DNA within the nuclei of living cells where it can act as a probe for real‑time imaging or at higher concentrations/illumination it can act as photosensitizer inducing phototoxicity.
Karmel S. Gkika +5 more
wiley +1 more source
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong +10 more
wiley +1 more source
Effect of safranal on the response of cancer cells to topoisomerase I inhibitors: Does sequence matter? [PDF]
Lozon L +5 more
europepmc +1 more source

